Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells

Blood

Volumn 116, Issue 14, 2010, Pages 2554-2558

  Hertlein, Erin ^a   Triantafillou, Georgia ^a   Sass, Ellen J ^a   Hessler, Joshua D ^a   Zhang, Xiaoli ^b   Jarjoura, David ^b   Lucas, David M ^a,b   Muthusamy, Natarajan ^a   Goldenberg, David M ^c   Lee, Robert J ^b   Byrd, John C ^a,b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CD74 ANTIGEN; FLUDARABINE; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOLIPOSOME; MILATUZUMAB; RITUXIMAB; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CELL DEATH; CELL SURFACE; CHRONIC LYMPHATIC LEUKEMIA; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 77957730947     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-11-253203     Document Type: Article

References (21)

1. Robak T, Moiseev SI, Dmoszynska A, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1756-1765.
2. Hallek M, Fingerle-Rowson G, Fink A-M, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R; FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). ASHAnnual Meeting Abstracts. 2008;112(11):325.
3. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079-4088. (Pubitemid 46211313)
4. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression- free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105(1):49-53. (Pubitemid 40053062)
5. Stein R, Mattes MJ, Cardillo TM, et al. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res. 2007;13(18 Pt 2):5556s-5563s. (Pubitemid 47510387)
6. Binsky I, Haran M, Starlets D, et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci U S A. 2007;104(33):13408- 13413. (Pubitemid 47293958)
7. Starlets D, Gore Y, Binsky I, et al. Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood. 2006;107(12): 4807-4816. (Pubitemid 43882632)
8. Gore Y, Starlets D, Maharshak N, et al. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem. 2008;283(5):2784-2792.
9. Leng L, Metz CN, Fang Y, et al. MIF signal transduction initiated by binding to CD74. J Exp Med. 2003;197(11):1467-1476. (Pubitemid 36686708)
10. Binsky I, Lantner F, Grabovsky V, et al. TAp63 Regulates VLA-4 Expression and Chronic Lymphocytic Leukemia Cell Migration to the Bone Marrow in a CD74-Dependent Manner. J Immunol. 2010;184(9):4761-4769.
11. Griffiths GL, Mattes MJ, Stein R, et al. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clin Cancer Res. 2003;9(17): 6567-6571. (Pubitemid 38031846)
12. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997. (Pubitemid 26189840)
13. Lucas DM, Edwards RB, Lozanski G, et al. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood. 2009;113(19):4656- 4666.
14. Johnson AJ, Lucas DM, Muthusamy N, et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood. 2006; 108(4):1334-1338. (Pubitemid 44232033)
15. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 2002;62(24):7190-7194. (Pubitemid 36025236)
16. Kurtova AV, Balakrishnan K, Chen R, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009;114(20):4441-4450.
17. Stein R, Qu Z, Cardillo TM, et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood. 2004;104(12):3705-3711. (Pubitemid 39564448)
18. Carnahan J, Stein R, Qu Z, et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol. 2007;44(6):1331-1341. (Pubitemid 44415959)
19. Mielgo A, Brondani V, Landmann L, et al. The CD44 standard/ezrin complex regulates Fas-mediated apoptosis in Jurkat cells. Apoptosis. 2007; 12(11):2051-2061. (Pubitemid 47498223)
20. Berkova Z, Tao RH, Samaniego F. Milatuzumab - a promising new immunotherapeutic agent. Expert Opin Investig Drugs. 2010;19(1):141-149.
21. Sapra P, Stein R, Pickett J, et al. Anti-CD74 anti-body- doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res. 2005;11(14):5257-5264. (Pubitemid 41003714)